Evidence map›Paper›PMID 32509883›Full record

ArticleJournal of immunology research2020

Successful Regulatory T Cell-Based Therapy Relies on Inhibition of T Cell Effector Function and Enrichment of FOXP3+ Cells in a Humanized Mouse Model of Skin Inflammation.

S Landman, V L de Oliveira, M Peppelman, E Fasse, E van Rijssen, S C Bauland, P van Erp, I Joosten, H J P M Koenen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

S LandmanLaboratory of Medical Immunology, Department of Laboratory Medicine, Radboud University Medical Center, Radboudumc. P.O. Box 9101, 6500 HB, Nijmegen, Netherlands.ORCID https://orcid.org/0000-0001-7792-9369
V L de OliveiraLaboratory of Medical Immunology, Department of Laboratory Medicine, Radboud University Medical Center, Radboudumc. P.O. Box 9101, 6500 HB, Nijmegen, Netherlands.
M PeppelmanLaboratory of Medical Immunology, Department of Laboratory Medicine, Radboud University Medical Center, Radboudumc. P.O. Box 9101, 6500 HB, Nijmegen, Netherlands.ORCID https://orcid.org/0000-0001-8636-2974
E FasseLaboratory of Medical Immunology, Department of Laboratory Medicine, Radboud University Medical Center, Radboudumc. P.O. Box 9101, 6500 HB, Nijmegen, Netherlands.ORCID https://orcid.org/0000-0001-8787-4648
E van RijssenLaboratory of Medical Immunology, Department of Laboratory Medicine, Radboud University Medical Center, Radboudumc. P.O. Box 9101, 6500 HB, Nijmegen, Netherlands.ORCID https://orcid.org/0000-0003-1534-5039
S C BaulandBauland Kliniek, Mill, Netherlands.
P van ErpDepartment of Dermatology, Radboud University Medical Center, Radboudumc. P.O. Box 9101, 6500 HB, Nijmegen, Netherlands.ORCID https://orcid.org/0000-0002-6955-8817
I JoostenLaboratory of Medical Immunology, Department of Laboratory Medicine, Radboud University Medical Center, Radboudumc. P.O. Box 9101, 6500 HB, Nijmegen, Netherlands.ORCID https://orcid.org/0000-0003-2950-4977
H J P M KoenenLaboratory of Medical Immunology, Department of Laboratory Medicine, Radboud University Medical Center, Radboudumc. P.O. Box 9101, 6500 HB, Nijmegen, Netherlands.ORCID https://orcid.org/0000-0003-1210-7502
Radboud University Nijmegen · NLKliniek ViaSana · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent clinical trials using regulatory T cells (Treg) support the therapeutic potential of Treg-based therapy in transplantation and autoinflammatory diseases. Despite these clinical successes, the effect of Treg on inflamed tissues, as well as their impact on immune effector function

methodsSCID beige mice were transplanted with human skin followed by intraperitoneal (IP) injection of 20-40 × 10

resultsWe confirmed that human Treg injection inhibits skin inflammation and the influx of effector T cells. As a novel finding, we demonstrate that human Treg injection led to a reduction of IL-17-secreting cells while promoting a relative increase in immunosuppressive FOXP3+ Treg in the human skin, indicating active immune regulation in controlling the local proinflammatory response. Consistent with the local control (skin), systemically (splenocytes), we observed that Treg injection led to lower frequencies of IFN

conclusionTaken together, we demonstrate that inhibition of skin inflammation by Treg infusion, next to a reduction of infiltrating effector T cells, is mediated by restoring both the local and systemic balance between cytokine-producing effector T cells and immunoregulatory T cells. This work furthers our understanding of Treg-based immunotherapy.

Indexed as

Skin TransplantationAnimalsCell ProliferationCells, CulturedDisease Models, AnimalFemaleForkhead Transcription FactorsHumansImmune ToleranceImmunotherapy, AdoptiveInflammationMiceMice, SCIDSkinT-Lymphocytes, RegulatoryT-Lymphocyte SubsetsForkhead Transcription FactorsFoxp3 protein, mouse

Identifiers

PMID32509883
PMCPMC7244960
OpenAlexW3025851815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.